Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | DNA polymerase I family protein | 0.0111 | 0.2689 | 1 |
Echinococcus granulosus | ATP dependent DNA helicase PIF1 | 0.0188 | 0.515 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.0093 | 0.2119 | 0.2119 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0058 | 0.1003 | 0.1003 |
Trypanosoma brucei | DNA repair and recombination helicase protein PIF7 | 0.0188 | 0.515 | 0.515 |
Loa Loa (eye worm) | hypothetical protein | 0.0111 | 0.2689 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0161 | 0.4281 | 0.4281 |
Onchocerca volvulus | DNA polymerase alpha catalytic subunit homolog | 0.0084 | 0.1843 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0188 | 0.515 | 1 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0188 | 0.515 | 0.515 |
Toxoplasma gondii | hypothetical protein | 0.0055 | 0.0893 | 1 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0188 | 0.515 | 0.515 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF6, putative | 0.0188 | 0.515 | 0.515 |
Giardia lamblia | Rrm3p helicase | 0.0188 | 0.515 | 1 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.0027 | 0.0003 | 0.0003 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0048 | 0.0669 | 0.0669 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0188 | 0.515 | 0.515 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0027 | 0.0003 | 0.0003 |
Trypanosoma brucei | DNA polymerase beta thumb, putative | 0.0048 | 0.0669 | 0.0669 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.034 | 1 | 1 |
Trypanosoma brucei | mitochondrial DNA polymerase beta-PAK | 0.0161 | 0.4281 | 0.4281 |
Trypanosoma brucei | unspecified product | 0.0027 | 0.0003 | 0.0003 |
Mycobacterium ulcerans | hypothetical protein | 0.0179 | 0.4861 | 0.5 |
Trypanosoma cruzi | DNA polymerase beta thumb, putative | 0.0048 | 0.0669 | 0.0669 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0027 | 0.0003 | 0.0003 |
Schistosoma mansoni | hypothetical protein | 0.0188 | 0.515 | 1 |
Entamoeba histolytica | DNA repair and recombination protein, putative | 0.0188 | 0.515 | 0.5 |
Plasmodium vivax | DNA polymerase alpha, putative | 0.005 | 0.0736 | 0.5 |
Leishmania major | mitochondrial DNA polymerase beta-PAK, putative | 0.0161 | 0.4281 | 0.4281 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.034 | 1 | 1 |
Echinococcus multilocularis | hypothetical protein | 0.0111 | 0.2689 | 0.3911 |
Schistosoma mansoni | hypothetical protein | 0.0093 | 0.2119 | 0.2502 |
Entamoeba histolytica | hypothetical protein, conserved | 0.0188 | 0.515 | 0.5 |
Trypanosoma brucei | DNA repair and recombination helicase protein PIF6 | 0.0188 | 0.515 | 0.515 |
Echinococcus granulosus | DNA polymerase subunit gamma | 0.0111 | 0.2689 | 0.3911 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0179 | 0.4861 | 0.5 |
Trypanosoma cruzi | DNA polymerase beta thumb, putative | 0.0048 | 0.0669 | 0.0669 |
Schistosoma mansoni | DNA polymerase gamma | 0.0111 | 0.2689 | 0.3911 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0188 | 0.515 | 0.515 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.034 | 1 | 1 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0027 | 0.0003 | 0.0003 |
Echinococcus multilocularis | ATP dependent DNA helicase PIF1 | 0.0188 | 0.515 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.